OBaris obtains the CHF 150,000 Kick to enable the painless delivery of injectable drugs
19.03.2024
Based on an octopus-inspired suction patch, OBaris enables the painless administration of injectable drugs. The ETH spin-off received the CHF 150,000 investment from Venture Kick to enhance patients' quality of life.
 OBaris’ team: CEO Dr. Nevena Paunovic and CSO David Klein Cerrejon
|
 |
Millions of patients face the discomfort of daily injections due to their dependence on medications that cannot be taken orally. OBaris (former Transire Bio) has developed a needle-free alternative, named “OctoPatch”, in the form of a painless suction patch applied to the inner cheek, which allows the drugs to efficiently enter the bloodstream.
OBaris aims to access the rapidly growing market of therapeutic peptides, with an overall size of ca. CHF 40 billion in 2023. Its goal is to provide a painless alternative to patients across multiple therapeutic indications, with a focus on metabolic diseases, such as diabetes, obesity, and osteoporosis. OBaris also aims to partner with leading pharmaceutical companies to make its solution available for an even broader population of patients.
OBaris will invest the CHF 150’000 from Venture Kick to validate its regulatory strategy and initiate the first meeting with the FDA, organize the scale-up manufacturing, and further prepare for the fundraising by meeting with international investors.
The founding team comprises CEO Nevena Paunoviç, CSO David Klein Cerrejon, Prof. Jean-Christophe Leroux, and Prof. Zhi Luo (advisory board). From April 2024, David and Nevena will swap roles, with David becoming the CEO and Nevena taking the role of CTO.
“Venture Kick program substantially accelerated our progress in the last nine months. The great questions raised during our pitches, the feedback we received afterwards, as well as the coaching during Kicker’s Camps, helped us to refine our business plan and improve our pitching skills,” highlighted Nevena Paunovic. “Additionally, the financial support enabled us to get first feedback from regulatory consultants and ensure our presence at one of the largest partnering conferences in the world.”
OBaris’ team: CEO Dr. Nevena Paunovic and CSO David Klein Cerrejon
OBaris aims to access the rapidly growing market of therapeutic peptides, with an overall size of ca. CHF 40 billion in 2023. Its goal is to provide a painless alternative to patients across multiple therapeutic indications, with a focus on metabolic diseases, such as diabetes, obesity, and osteoporosis. OBaris also aims to partner with leading pharmaceutical companies to make its solution available for an even broader population of patients.
OBaris will invest the CHF 150’000 from Venture Kick to validate its regulatory strategy and initiate the first meeting with the FDA, organize the scale-up manufacturing, and further prepare for the fundraising by meeting with international investors.
The founding team comprises CEO Nevena Paunoviç, CSO David Klein Cerrejon, Prof. Jean-Christophe Leroux, and Prof. Zhi Luo (advisory board). From April 2024, David and Nevena will swap roles, with David becoming the CEO and Nevena taking the role of CTO.
“Venture Kick program substantially accelerated our progress in the last nine months. The great questions raised during our pitches, the feedback we received afterwards, as well as the coaching during Kicker’s Camps, helped us to refine our business plan and improve our pitching skills,” highlighted Nevena Paunovic. “Additionally, the financial support enabled us to get first feedback from regulatory consultants and ensure our presence at one of the largest partnering conferences in the world.”
OBaris’ team: CEO Dr. Nevena Paunovic and CSO David Klein Cerrejon